Tetraphase Pharmaceuticals, Inc. Securities Litigation
On or around 10/10/2018 (Ongoing date of last review)
Filing Date: July 27, 2018
According to the Complaint, Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company") is a clinical-stage biopharmaceutical company that develops antibiotics for serious and life-threatening multidrug-resistant infections.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose: (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial’s primary endpoints (within the 10% non-inferiority margin); (2) The enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial’s primary endpoints; and (3) that, as a result of the foregoing, Defendants’ statements about Tetraphase’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
Company & Securities Information
Defendant: Tetraphase Pharmaceuticals, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: TTPH
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Edward Garity, et al. v. Tetraphase Pharmaceuticals, Inc., et al.
COURT: S.D. New York
DOCKET #: 18-CV-06797
JUDGE: Hon. Paul A. Engelmayer
DATE FILED: 07/27/2018
CLASS PERIOD START: 03/08/2017
CLASS PERIOD END: 02/13/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Glancy Prongay & Murray LLP (New York) 122 East 42nd Street, Suite 2920 , Glancy Prongay & Murray LLP (New York), NY 10168 (212) 682-5340 (212) 884-0988 ·